202 related articles for article (PubMed ID: 30560892)
21. Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer.
Merino D; Weber TS; Serrano A; Vaillant F; Liu K; Pal B; Di Stefano L; Schreuder J; Lin D; Chen Y; Asselin-Labat ML; Schumacher TN; Cameron D; Smyth GK; Papenfuss AT; Lindeman GJ; Visvader JE; Naik SH
Nat Commun; 2019 Feb; 10(1):766. PubMed ID: 30770823
[TBL] [Abstract][Full Text] [Related]
22. CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy.
Denard B; Jiang S; Peng Y; Ye J
BMC Cancer; 2018 Aug; 18(1):813. PubMed ID: 30103710
[TBL] [Abstract][Full Text] [Related]
23. Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer.
Himmel LE; Lustberg MB; DeVries AC; Poi M; Chen CS; Kulp SK
Exp Toxicol Pathol; 2016 Oct; 68(9):505-515. PubMed ID: 27555377
[TBL] [Abstract][Full Text] [Related]
24. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
[TBL] [Abstract][Full Text] [Related]
25. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer.
Dávila-González D; Choi DS; Rosato RR; Granados-Principal SM; Kuhn JG; Li WF; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Clin Cancer Res; 2018 Mar; 24(5):1152-1162. PubMed ID: 29301832
[No Abstract] [Full Text] [Related]
28. Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance.
Ruiz de Garibay G; Mateo F; Stradella A; Valdés-Mas R; Palomero L; Serra-Musach J; Puente DA; Díaz-Navarro A; Vargas-Parra G; Tornero E; Morilla I; Farré L; Martinez-Iniesta M; Herranz C; McCormack E; Vidal A; Petit A; Soler T; Lázaro C; Puente XS; Villanueva A; Pujana MA
Dis Model Mech; 2018 May; 11(5):. PubMed ID: 29666142
[TBL] [Abstract][Full Text] [Related]
29. Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
Marangoni E; Laurent C; Coussy F; El-Botty R; Château-Joubert S; Servely JL; de Plater L; Assayag F; Dahmani A; Montaudon E; Nemati F; Fleury J; Vacher S; Gentien D; Rapinat A; Foidart P; Sounni NE; Noel A; Vincent-Salomon A; Lae M; Decaudin D; Roman-Roman S; Bièche I; Piccart M; Reyal F
Clin Cancer Res; 2018 Jun; 24(11):2605-2615. PubMed ID: 29463559
[No Abstract] [Full Text] [Related]
30. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I
Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541
[TBL] [Abstract][Full Text] [Related]
31. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.
Kim JY; Gatenby RA
Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831
[TBL] [Abstract][Full Text] [Related]
32. Enhancing Abiraterone Acetate Efficacy in Androgen Receptor-positive Triple-negative Breast Cancer: Chk1 as a Potential Target.
Grellety T; Callens C; Richard E; Briaux A; Vélasco V; Pulido M; Gonçalves A; Gestraud P; MacGrogan G; Bonnefoi H; Cardinaud B
Clin Cancer Res; 2019 Jan; 25(2):856-867. PubMed ID: 30352905
[TBL] [Abstract][Full Text] [Related]
33. Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer.
Doddapaneni R; Patel K; Chowdhury N; Singh M
Sci Rep; 2017 Nov; 7(1):15824. PubMed ID: 29158480
[TBL] [Abstract][Full Text] [Related]
34. Ultrasound-targeted microbubble destruction improved the antiangiogenic effect of Endostar in triple-negative breast carcinoma xenografts.
Jing Y; Xiu-Juan Z; Hong-Jiao C; Zhi-Kui C; Qing-Fu Q; En-Sheng X; Li-Wu L
J Cancer Res Clin Oncol; 2019 May; 145(5):1191-1200. PubMed ID: 30805775
[TBL] [Abstract][Full Text] [Related]
35. The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE".
Savas P; Teo ZL; Lefevre C; Flensburg C; Caramia F; Alsop K; Mansour M; Francis PA; Thorne HA; Silva MJ; Kanu N; Dietzen M; Rowan A; Kschischo M; Fox S; Bowtell DD; Dawson SJ; Speed TP; Swanton C; Loi S
PLoS Med; 2016 Dec; 13(12):e1002204. PubMed ID: 28027312
[TBL] [Abstract][Full Text] [Related]
36. Catalog of genetic progression of human cancers: breast cancer.
Desmedt C; Yates L; Kulka J
Cancer Metastasis Rev; 2016 Mar; 35(1):49-62. PubMed ID: 26951551
[TBL] [Abstract][Full Text] [Related]
37. The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers.
Tury S; Assayag F; Bonin F; Chateau-Joubert S; Servely JL; Vacher S; Becette V; Caly M; Rapinat A; Gentien D; de la Grange P; Schnitzler A; Lallemand F; Marangoni E; Bièche I; Callens C
J Pathol; 2018 Sep; 246(1):103-114. PubMed ID: 29876931
[TBL] [Abstract][Full Text] [Related]
38. Peginterferon Beta-1a Shows Antitumor Activity as a Single Agent and Enhances Efficacy of Standard of Care Cancer Therapeutics in Human Melanoma, Breast, Renal, and Colon Xenograft Models.
Boccia A; Virata C; Lindner D; English N; Pathan N; Brickelmaier M; Hu X; Gardner JL; Peng L; Wang X; Zhang X; Yang L; Perron K; Yco G; Kelly R; Gamez J; Scripps T; Bennett D; Joseph IB; Baker DP
J Interferon Cytokine Res; 2017 Jan; 37(1):20-31. PubMed ID: 27835061
[TBL] [Abstract][Full Text] [Related]
39. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
[TBL] [Abstract][Full Text] [Related]
40. A novel patient-derived xenograft model for claudin-low triple-negative breast cancer.
Matossian MD; Burks HE; Bowles AC; Elliott S; Hoang VT; Sabol RA; Pashos NC; O'Donnell B; Miller KS; Wahba BM; Bunnell BA; Moroz K; Zea AH; Jones SD; Ochoa AC; Al-Khami AA; Hossain F; Riker AI; Rhodes LV; Martin EC; Miele L; Burow ME; Collins-Burow BM
Breast Cancer Res Treat; 2018 Jun; 169(2):381-390. PubMed ID: 29392581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
